Skinvisible Pharmaceuticals (OTCQB: SKVI) is a topical and transdermal product development company with a proprietary drug delivery system, Invisicare, that improves how ingredients are delivered to and through the skin including the medicinal components of marijuana; specifically, CBD (cannabidiol) and the psychoactive marijuana ingredient THC (tetrahydrocannabinol). The key to Skinvisible’s patented technology and trademarked Invisicare family of polymer delivery vehicles is its formula and process for combining hydrophilic and hydrophobic polymers into stable complexes in water emulsions. Applications of this novel technology are discussed in a recent article that says in part, “H7N9 (a type of avian influenza virus) could be the one to cause the next global flu pandemic, the World Health Organization (WHO) warns (http://cnw.fm/MXEb0). Luckily, the flu prophylactic market is already offering some adequate options, and DermSafe® by Skinvisible, Inc. (OTCQB: SKVI) subsidiary Skinvisible Pharmaceuticals, Inc. is one of them. In June, Skinvisible announced the first international sale of DermSafe in China – a country that’s known to have the first reported cases of human avian influenza infections.”
Read the full article
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Read More
Skinvisible Pharmaceuticals, Inc. (SKVI) Could Have the Solution to the Flu Epidemic
